BioCentury | Feb 4, 2021
Deals

Jazz strikes another chord in neuroscience via $7.2B GW pickup

...U.S. in July 2020, a few months after obtaining territorial rights in a deal with PharmaMar S.A....
BioCentury | Jan 30, 2021
Translation in Brief

Gladstone-UCSF research center to focus on brain diseases; plus a mammography-based prediction algorithm, PharmaMar and an intracellular glycoprotein that blocks phagocytosis

...than Veklury remdesivir. The team had identified Aplidin’s target, EEF1A2, during research to find drug repurposing candidates for COVID-19, and PharmaMar S.A....
...Stanniocalcin 1 Danielle Golovin Aplidin, plitidepsin Veklury, remdesivir (GS-5734) Icahn School of Medicine at Mount Sinai University of California San Francisco PharmaMar S.A. Gilead...
BioCentury | Dec 3, 2020
Product Development

After Phase III miss, PharmaMar and Jazz may need new monotherapy trial to confirm cancer drug’s benefit

...By Paul Bonanos, Associate Editor PharmaMar will likely need to conduct a new study of Zepzelca...
...grant full approval.If it did not show a survival benefit, Iannone said he expected that PharmaMar S.A....
...the market.Jazz paid PharmaMar $200 million up front in December 2019 to gain Zepzelca’s U.S. rights.PharmaMar...
BioCentury | Sep 8, 2020
Management Tracks

Black Diamond names Humphrey CMO; plus Edmondson to lead chemistry at Nimbus, Recce, Amarna and more

...Sept. 25. President and CEO Kenneth Berlin will serve as interim CFO of the immunotherapy company.PharmaMar...
...serve as the unit’s VP and global head. Jimeno was VP of clinical development at PharmaMar...
BioCentury | Jun 17, 2020
Product Development

June 16 Quick Takes: Takeda out-licenses neurology pipeline to Neurocrine; plus Illumina challenge blocks BGI, FDA approves a pair of firsts and more

...cancer portfolio FDA granted accelerated approval to Zepzelca lurbinectedin from Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and PharmaMar S.A....
...II BioCentury Staff teplizumab (MGA031, PRV-031) Ilaris, canakinumab (ACZ885) Zepsyre, lurbinectedin (PM01183, PM1183, tryptamicidin) avalglucosidase alfa, NeoGAA, Neo-GAA (GZ402666) Provention Jazz Pharmaceuticals Inc. PharmaMar S.A. Novartis Takeda...
BioCentury | Mar 20, 2020
Translation in Brief

Vaxxas' temperature-stable, low-dose vaccine patch; plus Stanford screen for 3-D tumor targets, new invasion mechanism for SARS-CoV-2 and PharmaMar

...slated for completion by year end. PharmaMar seeks to repurpose multiple myeloma drug for COVID-19 PharmaMar S.A....
...infection by the alpha coronavirus HCoV-229E with nanomolar potency. While SARS-CoV-2 is a beta coronavirus, PharmaMar...
...1 α 2 Influenza A HA - Influenza A virus hemagglutinin BioCentury Staff Bill & Melinda Gates Foundation PharmaMar S.A. Stanford...
BioCentury | Feb 18, 2020
Regulation

Regulatory Roundup: PharmaMar-Jazz, BioCryst products under FDA review; plus EU approvals of Vyndaqel, Beovu; and more

...treat a form of amyloidosis. FDA granted Priority Review to an NDA for lurbinectedin from PharmaMar S.A....
...accelerated approval of the Pol II inhibitor, whose PDUFA date is Aug. 16. In December, PharmaMar...
...Transthyretin VEGF - Vascular endothelial growth factor Paul Bonanos, Associate Editor Zepsyre, lurbinectedin (PM01183, PM1183, tryptamicidin) BCX7353 vadadustat (MT-6548, akb-6548) PharmaMar S.A. Jazz...
BioCentury | Feb 8, 2020
Emerging Company Profile

Serentrix: pain relief without side effects

...pain. At least one company is still pursuing the target. The Sylentis S.A. subsidiary of PharmaMar S.A....
BioCentury | Dec 19, 2019
Company News

PharmaMar deal adds late-stage asset to Jazz’s growing cancer pipeline

...Jazz’s deal to gain exclusive, U.S. rights to PharmaMar’s Zepsyre marks the company’s third cancer partnership...
...cell lung cancer as it continues to expand its pipeline beyond its flagship narcolepsy programs. PharmaMar S.A....
...million in commercial milestones from Jazz Pharmaceuticals plc (NASDAQ:JAZZ), plus high-teen to 30% tiered royalties. PharmaMar...
BioCentury | Aug 19, 2019
Company News

Aug. 19 Company Quick Takes: PharmaMar gets bump on FDA timeline in SCLC; plus Shionogi, Vanda and Moderna

...PharmaMar seeking accelerated approval of SCLC candidate PharmaMar S.A. (Madrid:PHM) climbed €0.46 (29%) to €2.06 after the...
...Bonanos, Associate Editor and Mary Romeo, Assistant Editor cefiderocol (S-649266) Hetlioz, tasimelteon (VEC-162) MRNA-1893 Zepsyre, lurbinectedin (PM01183, PM1183, tryptamicidin) Moderna Inc. PharmaMar S.A. Shionogi...
Items per page:
1 - 10 of 290
BioCentury | Feb 4, 2021
Deals

Jazz strikes another chord in neuroscience via $7.2B GW pickup

...U.S. in July 2020, a few months after obtaining territorial rights in a deal with PharmaMar S.A....
BioCentury | Jan 30, 2021
Translation in Brief

Gladstone-UCSF research center to focus on brain diseases; plus a mammography-based prediction algorithm, PharmaMar and an intracellular glycoprotein that blocks phagocytosis

...than Veklury remdesivir. The team had identified Aplidin’s target, EEF1A2, during research to find drug repurposing candidates for COVID-19, and PharmaMar S.A....
...Stanniocalcin 1 Danielle Golovin Aplidin, plitidepsin Veklury, remdesivir (GS-5734) Icahn School of Medicine at Mount Sinai University of California San Francisco PharmaMar S.A. Gilead...
BioCentury | Dec 3, 2020
Product Development

After Phase III miss, PharmaMar and Jazz may need new monotherapy trial to confirm cancer drug’s benefit

...By Paul Bonanos, Associate Editor PharmaMar will likely need to conduct a new study of Zepzelca...
...grant full approval.If it did not show a survival benefit, Iannone said he expected that PharmaMar S.A....
...the market.Jazz paid PharmaMar $200 million up front in December 2019 to gain Zepzelca’s U.S. rights.PharmaMar...
BioCentury | Sep 8, 2020
Management Tracks

Black Diamond names Humphrey CMO; plus Edmondson to lead chemistry at Nimbus, Recce, Amarna and more

...Sept. 25. President and CEO Kenneth Berlin will serve as interim CFO of the immunotherapy company.PharmaMar...
...serve as the unit’s VP and global head. Jimeno was VP of clinical development at PharmaMar...
BioCentury | Jun 17, 2020
Product Development

June 16 Quick Takes: Takeda out-licenses neurology pipeline to Neurocrine; plus Illumina challenge blocks BGI, FDA approves a pair of firsts and more

...cancer portfolio FDA granted accelerated approval to Zepzelca lurbinectedin from Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and PharmaMar S.A....
...II BioCentury Staff teplizumab (MGA031, PRV-031) Ilaris, canakinumab (ACZ885) Zepsyre, lurbinectedin (PM01183, PM1183, tryptamicidin) avalglucosidase alfa, NeoGAA, Neo-GAA (GZ402666) Provention Jazz Pharmaceuticals Inc. PharmaMar S.A. Novartis Takeda...
BioCentury | Mar 20, 2020
Translation in Brief

Vaxxas' temperature-stable, low-dose vaccine patch; plus Stanford screen for 3-D tumor targets, new invasion mechanism for SARS-CoV-2 and PharmaMar

...slated for completion by year end. PharmaMar seeks to repurpose multiple myeloma drug for COVID-19 PharmaMar S.A....
...infection by the alpha coronavirus HCoV-229E with nanomolar potency. While SARS-CoV-2 is a beta coronavirus, PharmaMar...
...1 α 2 Influenza A HA - Influenza A virus hemagglutinin BioCentury Staff Bill & Melinda Gates Foundation PharmaMar S.A. Stanford...
BioCentury | Feb 18, 2020
Regulation

Regulatory Roundup: PharmaMar-Jazz, BioCryst products under FDA review; plus EU approvals of Vyndaqel, Beovu; and more

...treat a form of amyloidosis. FDA granted Priority Review to an NDA for lurbinectedin from PharmaMar S.A....
...accelerated approval of the Pol II inhibitor, whose PDUFA date is Aug. 16. In December, PharmaMar...
...Transthyretin VEGF - Vascular endothelial growth factor Paul Bonanos, Associate Editor Zepsyre, lurbinectedin (PM01183, PM1183, tryptamicidin) BCX7353 vadadustat (MT-6548, akb-6548) PharmaMar S.A. Jazz...
BioCentury | Feb 8, 2020
Emerging Company Profile

Serentrix: pain relief without side effects

...pain. At least one company is still pursuing the target. The Sylentis S.A. subsidiary of PharmaMar S.A....
BioCentury | Dec 19, 2019
Company News

PharmaMar deal adds late-stage asset to Jazz’s growing cancer pipeline

...Jazz’s deal to gain exclusive, U.S. rights to PharmaMar’s Zepsyre marks the company’s third cancer partnership...
...cell lung cancer as it continues to expand its pipeline beyond its flagship narcolepsy programs. PharmaMar S.A....
...million in commercial milestones from Jazz Pharmaceuticals plc (NASDAQ:JAZZ), plus high-teen to 30% tiered royalties. PharmaMar...
BioCentury | Aug 19, 2019
Company News

Aug. 19 Company Quick Takes: PharmaMar gets bump on FDA timeline in SCLC; plus Shionogi, Vanda and Moderna

...PharmaMar seeking accelerated approval of SCLC candidate PharmaMar S.A. (Madrid:PHM) climbed €0.46 (29%) to €2.06 after the...
...Bonanos, Associate Editor and Mary Romeo, Assistant Editor cefiderocol (S-649266) Hetlioz, tasimelteon (VEC-162) MRNA-1893 Zepsyre, lurbinectedin (PM01183, PM1183, tryptamicidin) Moderna Inc. PharmaMar S.A. Shionogi...
Items per page:
1 - 10 of 290